* Galectin Therapeutics Inc GALT.OQ GALT.O is expected
to show
no change in quarterly revenue when it reports results on
August 12 (estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Galectin Therapeutics
Inc is
for a loss of 16 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $11.00, above its last closing price
of $2.14.
This summary was machine generated August 9 at 18:31 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)